In keeping with its 2027 cost-cutting deadline, Merck & Co. announced another round of layoffs at its global headquarters in Rahway, New Jersey. | Merck continues sweeping staff reductions, laying off ...
On Wednesday, BioMarin unveiled detailed results from the phase 3 CANOPY-HCH-3 trial assessing Voxzogo in children with hypochondroplasia (HCH), a milder form of achondroplasia, where the company ...
Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...
Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...
Spying a “golden decade” beyond the branded drug industry’s looming patent cliff, Sandoz is making big bets on its biosimilar ...
In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...
Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...
Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again ...
With the help of AI, AstraZeneca’s three-in-one inhaler Breztri has a new furry mascot to help it stand tall over the crowded ...
After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results